Repro Med Systems, Inc. (KRMD): Price and Financial Metrics

Repro Med Systems, Inc. (KRMD): $2.35

0.12 (+5.38%)

POWR Rating

Component Grades













KRMD Stock Summary

  • The ratio of debt to operating expenses for Repro Med Systems Inc is higher than it is for about merely 7.84% of US stocks.
  • With a year-over-year growth in debt of 152.26%, Repro Med Systems Inc's debt growth rate surpasses 92.84% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Repro Med Systems Inc is reporting a growth rate of 432.92%; that's higher than 94.94% of US stocks.
  • Stocks that are quantitatively similar to KRMD, based on their financial statements, market capitalization, and price volatility, are XXII, ATEC, ACRX, ECOR, and SIBN.
  • Visit KRMD's SEC page to see the company's official filings. To visit the company's web site, go to

KRMD Valuation Summary

  • KRMD's price/sales ratio is 6.9; this is 39.21% lower than that of the median Healthcare stock.
  • Over the past 243 months, KRMD's EV/EBIT ratio has gone down 9.
  • KRMD's price/sales ratio has moved up 5 over the prior 243 months.

Below are key valuation metrics over time for KRMD.

Stock Date P/S P/B P/E EV/EBIT
KRMD 2021-08-31 6.9 3.9 -48.5 -27.3
KRMD 2021-08-30 6.8 3.8 -47.9 -26.9
KRMD 2021-08-27 6.7 3.8 -47.7 -26.8
KRMD 2021-08-26 6.9 3.9 -48.8 -27.5
KRMD 2021-08-25 6.7 3.8 -47.6 -26.7
KRMD 2021-08-24 7.0 4.0 -49.3 -27.9

KRMD Growth Metrics

    The 5 year price growth rate now stands at 3033.33%.
  • The 3 year price growth rate now stands at 364.93%.
  • Its 5 year revenue growth rate is now at 100.19%.
KRMD's revenue has moved down $3,388,269 over the prior 18 months.

The table below shows KRMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 23.49018 -4.31951 -4.562823
2021-09-30 21.05689 -5.314138 -4.329093
2021-06-30 21.09666 -6.227022 -2.98614
2021-03-31 23.27739 -3.502212 -2.937629
2020-12-31 24.17645 -0.743323 -1.212063
2020-09-30 26.34136 1.791071 -0.457692

KRMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KRMD has a Quality Grade of D, ranking ahead of 19.43% of graded US stocks.
  • KRMD's asset turnover comes in at 0.501 -- ranking 94th of 186 Medical Equipment stocks.
  • CSII, NVRO, and XENT are the stocks whose asset turnover ratios are most correlated with KRMD.

The table below shows KRMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.501 0.601 -0.483
2021-03-31 0.531 0.618 -0.535
2020-12-31 0.646 0.618 -0.188
2020-09-30 0.852 0.630 -0.036
2020-06-30 1.170 0.634 0.047
2020-03-31 1.753 0.636 0.245

KRMD Price Target

For more insight on analysts targets of KRMD, see our KRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.17 Average Broker Recommendation 1.83 (Hold)

KRMD Stock Price Chart Interactive Chart >

Price chart for KRMD

KRMD Price/Volume Stats

Current price $2.35 52-week high $4.83
Prev. close $2.23 52-week low $1.90
Day low $2.23 Volume 7,800
Day high $2.35 Avg. volume 56,684
50-day MA $2.65 Dividend yield N/A
200-day MA $2.96 Market Cap 105.44M

Repro Med Systems, Inc. (KRMD) Company Bio

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.

KRMD Latest News Stream

Event/Time News Detail
Loading, please wait...

KRMD Latest Social Stream

Loading social stream, please wait...

View Full KRMD Social Stream

Latest KRMD News From Around the Web

Below are the latest news stories about Repro Med Systems Inc that investors may wish to consider to help them evaluate KRMD as an investment opportunity.

Analysts Estimate Repro Med Systems, Inc. (KRMD) to Report a Decline in Earnings: What to Look Out for

Repro Med Systems, Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 23, 2022

CORRECTING and REPLACING KORU Medical Systems to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

CHESTER, N.Y., February 22, 2022--First paragraph, first sentence of release dated February 16, 2022, should read: Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022. [instead of Repro Med Systems, Inc. dba K

Yahoo | February 22, 2022

Those who invested in Repro Med Systems (NASDAQ:KRMD) five years ago are up 523%

It might be of some concern to shareholders to see the Repro Med Systems, Inc. ( NASDAQ:KRMD ) share price down 16% in...

Yahoo | January 26, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

CHESTER, N.Y., December 21, 2021--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols.

Yahoo | December 21, 2021

Acuitas Investments LLC Buys 63,321 Shares of Repro Med Systems, Inc. (NASDAQ:KRMD)

Acuitas Investments LLC increased its holdings in shares of Repro Med Systems, Inc. (NASDAQ:KRMD) by 33.9% during the third quarter, Holdings Channel reports. The fund owned 250,342 shares of the company’s stock after purchasing an additional 63,321 shares during the period. Acuitas Investments LLC’s holdings in Repro Med Systems were worth $713,000 at the end […]

Dakota Financial News | December 14, 2021

Read More 'KRMD' Stories Here

KRMD Price Returns

1-mo -11.32%
3-mo -26.56%
6-mo -31.69%
1-year -44.96%
3-year 35.06%
5-year 424.55%
YTD -21.67%
2021 -50.17%
2020 -7.81%
2019 295.76%
2018 32.00%
2017 150.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.746 seconds.